ClinicalTrials.gg
RecruitingNCT07725796Updated Oct 13, 2026

A Phase 1 Dose-escalation Study of UGN-501 Administered Intravesically in Adult Participants With Recurrent NMIBC

A Phase 1 interventional study of UGN-501 in Bladder (Urothelial, Transitional Cell) Cancer, NMIBC and Urothelial Carcinoma Bladder, sponsored by UroGen Pharma, Inc., a subsidiary of UroGen Pharma Ltd.. Recruiting at 15 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.

Primary conditionNon-Muscle Invasive Bladder NeoplasmsRegistry: NeoplasmsReclassifiedWhy we changed it
Registry
Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Non-Muscle Invasive Bladder Neoplasms
Why
  1. The study's listed conditions name Non-Muscle Invasive Bladder Neoplasms, a narrower term within Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by UroGen Pharma, Inc., a subsidiary of UroGen Pharma Ltd. · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2026; still recruiting 1 month later.
Updated Oct 13, 2026Now RecruitingSite recruiting status changed+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 114 studies in Non-Muscle Invasive Bladder Neoplasms with a site in United States — 39 open to participants now, 60 under way, 15 of them phase 3. Non-Muscle Invasive Bladder Neoplasms · United States.

Planned enrollment
62nd of 93
30 · median 55
Started
2026
with 8 others
Phase 1
20 of 114
5 open now
Primary completion
2029-08
later than 48 of 59 live
Registered
112th of 114
by date

Among the 114 studies in Non-Muscle Invasive Bladder Neoplasms with a site in United States, this one is the 62nd largest by planned enrollment of the 93 interventional ones that give a count, is one of 9 that started in 2026, is one of 20 in phase 1, reaches primary completion later than 48 of the 59 other live ones, and was the 112th registered.

Non-Muscle Invasive Bladder Neoplasms

295 studies on the registry are indexed under Non-Muscle Invasive Bladder Neoplasms; 127 are open to participants now.

Browse Non-Muscle Invasive Bladder Neoplasms studies →

Open to participants now

39 of the 114 studies in Non-Muscle Invasive Bladder Neoplasms with a site in United States are open now. Recruiting first, the newest first:

33 more — sign in →

All 39 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 93 Non-Muscle Invasive Bladder Neoplasms studies recruiting now, 78 (84%) set no upper age limit and 5 (5%) stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 114 studies in Non-Muscle Invasive Bladder Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This study is being conducted to evaluate the safety and tolerability of UGN-501 administered intravesically in adult participants with recurrent non-muscle invasive bladder cancer (NMIBC) and to determine the recommended Phase 2 dose (RP2D).

Read the detailed description

This is a Phase 1, open-label, dose-escalation, multicenter study to investigate the safety, tolerability, immunogenicity, and pharmacokinetics (PK) of UGN-501, a chimeric oncolytic adenovirus, administered intravesically in participants with recurrent NMIBC.

Eligible participants will enter a 12-week Induction Period. Participants with Ta and/or T1 disease who do not have disease recurrence, and participants with carcinoma in situ (CIS) who have a complete response (CR) at Week 12, will enter the Maintenance Period. Disease assessments will be performed every 3 months through Month 15, or until disease recurrence, disease progression, or death, whichever occurs first.

The maximum duration of participation is approximately 15 months.

This master protocol may include multiple study intervention arms designed to independently evaluate UGN-501. Any additional study intervention arms or dose expansions will be added by protocol amendment.

03

Conditions studied

  • Bladder (Urothelial, Transitional Cell) Cancer
  • NMIBC
  • Urothelial Carcinoma Bladder
  • Urothelial Carcinoma in Situ
  • Urothelial Carcinoma Recurrent
  • Urothelial Carcinoma of the Urinary Bladder
  • Non-Muscle Invasive Bladder Carcinoma
  • Non-muscle Invasive Bladder Cancer (NMIBC)

Browse trials for

Keywords

  • CIS
  • Ta bladder cancer
  • T1 bladder cancer
  • BCG-unresponsive NMIBC
  • BCG-exposed NMIBC
  • BCG-intolerant NMIBC
  • Intravesical therapy
  • Oncolytic Virus
04

In context

Non-Muscle Invasive Bladder Neoplasms Reclassified

295 studies on the registry are indexed under Non-Muscle Invasive Bladder Neoplasms; 127 are open to participants now.

This study's planned enrollment of 30 is below the median of 61 across 232 interventional studies indexed under Non-Muscle Invasive Bladder Neoplasms.

Browse Non-Muscle Invasive Bladder Neoplasms studies →

Lead sponsor

This is the only study on the registry with UroGen Pharma, Inc., a subsidiary of UroGen Pharma Ltd. as lead sponsor.

Compared within Non-Muscle Invasive Bladder Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

The criteria were revised on the registry on Oct 13, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participant must be 18 years of age or older at the time of signing .
  2. Has confirmed recurrent non-muscle invasive bladder cancer (NMIBC) with high-grade Ta and/or T1 disease and/or carcinoma in situ (CIS), or recurrent low-grade Ta and/or T1 disease.
  3. Participants with high-grade Ta and/or T1 disease and/or CIS must meet one of the following criteria:

    • Has BCG-unresponsive disease, defined as:
    • persistent or recurrent CIS alone or with recurrent Ta/T1 disease within 12 months of completion of adequate BCG therapy; or
    • recurrent high-grade Ta/T1 disease within 6 months of completion of adequate BCG therapy; or
    • high-grade T1 disease at the first evaluation following a BCG induction course.

    Adequate BCG therapy is defined as at least 5 of 6 doses of an initial induction course plus either at least 2 of 3 doses of maintenance therapy or at least 2 of 6 doses of a second induction course. Participants with BCG-unresponsive disease also must be unwilling or unfit to undergo radical cystectomy.

    • Is BCG-exposed, defined as high-grade persistent or recurrent NMIBC within 24 months of the last dose of BCG but not meeting the definition of BCG-unresponsive disease, and received at least 5 of 6 doses of an initial induction course of BCG.
    • Is BCG intolerant, defined as the inability to tolerate at least 1 full induction course of BCG.
    • Has a high-grade Ta tumor ≤3 cm and failed at least 1 previous course of therapy, such as TURBT plus an adjuvant induction course of intravesical chemotherapy.
  4. Participants with low-grade disease must meet one of the following criteria:

    • Ta tumors recurring within 1 year.
    • Ta solitary tumor >3 cm.
    • Ta multifocal tumors.
    • T1 tumors.
  5. All visible papillary tumors must be resected and obvious areas of CIS fulgurated during Screening or within 6 weeks before Screening. Participants with T1 disease should have a re-staging TURBT during Screening or within 6 weeks before Screening. Enhanced cystoscopy, such as blue light cystoscopy or other locally accepted modalities, is permitted, but the same modality must be used for all subsequent disease assessments.
  6. Has performance status score ≤2.
  7. Has no concomitant upper tract urothelial carcinoma (UTUC) or urothelial carcinoma within the prostatic stroma. Freedom from upper tract disease, if clinically indicated, must be demonstrated by no evidence of upper tract tumor by either IV pyelogram, retrograde pyelogram, CT urogram with or without contrast, MRI urogram with or without contrast, or ureteroscopy with ureteral washing for cytology, performed within 6 months of enrollment. Participants with urothelial carcinoma involving the prostatic urethra, where carcinoma is confined to the ducts and/or epithelium, may be included after a restaging TURBT is performed to rule out more extensive disease involving the prostatic stroma.
  8. Participants with prostate cancer may be eligible if, after surgery or radiation, they do not meet criteria for biochemical recurrence, or if they are on active surveillance at very low, low, or favorable risk for progression, defined as Gleason Grade Group 1 or 2, Gleason score ≤7, prostate-specific antigen \<20 ng/dL, and cT1-cT2b, at the discretion of the investigator.
  9. Has adequate organ and bone marrow function within 14 days of treatment initiation, as determined by routine laboratory tests:

    • Leukocytes ≥3000/μL.
    • ≥1500/μL.
    • ≥100,000/μL.
    • ≥9.0 g/dL.
    • Total ≤1.5 × (ULN).
    • (AST) ≤2.5 × ULN.
    • Alanine aminotrasferase (ALT) ≤2.5 × ULN.
    • Alkaline phosphatase ≤2.5 × ULN.
    • Estimated ≥30 mL/min using the Cockcroft-Gault equation.
  10. Has a >12 months.
  11. Participants and participant partners must agree to follow and barrier method requirements consistent with local regulations and the protocol during the study intervention period and for at least 12 weeks after the last study intervention instillation.
  12. Is willing and able to sign informed consent and comply with the requirements and restrictions listed in the informed consent form and protocol.

Exclusion criteria

Exclusion Criteria:

  1. Current or previous evidence of muscle invasive, locally advanced nonresectable, or urothelial carcinoma, including T2, T3, T4, and/or stage IV disease.
  2. Current systemic therapy for bladder cancer.
  3. Prior treatment with any human adenovirus-based therapy, such as nadofaragene firadenovec-vncg or cretostimogene grenadenorepvec.
  4. Intravesical therapy within 4 weeks before starting study intervention, including but not limited to BCG, chemotherapy, and nogapendekin alfa inbakicept.
  5. Participation in a study of an agent with receipt of study therapy, or receipt of an investigational device, within 4 weeks before the first dose of study intervention.
  6. Receipt of immune modulator therapy within 5 half-lives of starting study intervention, including but not limited to pembrolizumab, BCG, and nogapendekin alfa inbakicept.
  7. Receipt of a vaccine or anti-viral agent within 2 weeks before starting study intervention.
  8. Active infection requiring systemic therapy, including urinary tract infection. Participants may enter the study once the infection is satisfactorily treated.
  9. state, including but not limited to infection or any condition that required systemic immunosuppressive treatment in the past 2 years, such as active systemic disease or solid organ or stem cell transplant. Short courses (≤14 days) of for medical reasons without anticancer intent, such as atopic dermatitis, psoriasis, infection, or allergic reaction, are permitted if the last dose was at least 4 weeks before the first dose of study intervention.
  10. Any medical, psychological, familial, sociological, or geographical condition that, in the opinion of the investigator, would preclude participation in the study.
  11. History of of another organ system within the past 5 years, except previously treated UTUC, basal cell carcinoma or squamous cell carcinoma of the skin, and/or prostate cancer meeting protocol-specified criteria.
  12. Cannot tolerate intravesical dosing or intravesical surgical manipulation.
  13. Known allergy or to any of the study interventions or any study intervention .
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

06

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    UGN-501 Dose Escalation (Part 1)

    Dose escalation of UGN-501 in participants with recurrent NMIBC with high grade (HG) Ta and/or T1 disease and/or CIS or recurrent low grade (LG) Ta and/or T1 disease.

    Biological: UGN-501

Interventions

  • BiologicalUGN-501

    UGN-501 is administered by intravesical instillation into the bladder. Participants receive 6 once-weekly instillations during the Induction Period. Participants eligible for maintenance receive 3 once-weekly instillations quarterly from Month 3 through Month 12.

07

What researchers measure

Primary outcomes

  1. Incidence of dose-limiting toxicities (DLTs) and treatment-emergent adverse events (TEAEs)

    The number of participants with each type of event will be summarized.

    Time frame: Up to 15 Months

  2. Concentration of UGN-501 in blood and urine

    Data will be summarized using descriptive statistics.

    Time frame: Up to 12 Weeks

  3. Complete response rate (CRR)

    CRR is defined as the proportion of CIS participants who achieved CR at the Week 12 (3-month) Visit.

    Time frame: 3 Months

  4. Recurrence-free survival (RFS) rate

    RFS rate is defined as the proportion of participants with Ta/T1 disease who are recurrence-free at the 6-month Visit.

    Time frame: 6 Months

Secondary outcomes

  1. Presence of anti-drug antibodies (ADA) in serum

    The number of participants with ADA will be summarized.

    Time frame: Up to 12 Weeks

  2. UGN-501 maximum concentration (Cmax) following single and repeat dose administration

    Data will be summarized using descriptive statistics

    Time frame: Up to 12 Weeks

  3. UGN-501 area under the concentration-time curve (AUC) following single and repeat dose administration

    Data will be summarized using descriptive statistics.

    Time frame: Up to 12 Weeks

  4. UGN-501 terminal half-life (t1/2) following single and repeat dose administration

    Data will be summarized using descriptive statistics.

    Time frame: Up to 12 Weeks

  5. UGN-501 time to maximum concentration (tmax) following single and repeat dose administration

    Data will be summarized using descriptive statistics.

    Time frame: Up to 12 Weeks

  6. UGN-501 concentration at the end of a dosing interval (Ctau) following single and repeat dose administration

    Data will be summarized using descriptive statistics.

    Time frame: Up to 12 Weeks

  7. Evaluation of viral shedding in urine following singe and repeat dose administration.

    Data will be summarized using descriptive statistics.

    Time frame: Up to 12 Weeks

08

Study locations

6 of 15 sites recruiting
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Aug 2029, 34 months after the start.

Of 24 phase 1 interventional studies under Non-Muscle Invasive Bladder Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 61. This study's planned 34 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 21, 2026
First posted
Jul 24, 2026
StartActual
Sep 28, 2026
Primary completionEst.
Aug 2, 2029
CompletionEst.
Aug 2, 2029
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 13, 2026
Sites
5 sites added, 1 site removed. 10 sites changed recruiting status (5 now recruiting, 5 now not yet recruiting)
Show 10 sites
  • East Valley Urology Center of Arizona · Queen Creek, United Statesno status→Recruiting
  • Michael G Oefelein Clinical Trials · Bakersfield, United Statesno status→Recruiting
  • Urology Center of Southern California · Murrieta, United Statesno status→Recruiting
  • Brigham and Women's Hospital · Boston, United Statesno status→Not yet recruiting
  • University of Nebraska Medical Center · Omaha, United Statesno status→Not yet recruiting
  • SUNY Upstate Medical University · Syracuse, United Statesno status→Not yet recruiting
  • University of Pennsylvania-Perelman Center for Advanced Medicine · Philadelphia, United Statesno status→Not yet recruiting
  • START Carolinas · Myrtle Beach, United Statesno status→Recruiting
  • UPNT Research Institute · Arlington, United Statesno status→Recruiting
  • Urology Austin · Austin, United Statesno status→Not yet recruiting
Show 5 added (5 United States)
  • University of Colorado Cancer Center · Aurora, United States
  • University of Miami · Miami, United States
  • Michigan Institute of Urology · Troy, United States
  • Oregon Health & Science University · Portland, United States
  • Renovatio Clinical · The Woodlands, United States
Show 1 removed
  • Ichan School of Medicine at Mount Sinai · New York, United States
Oct 13, 2026
Start date
Sep 30, 2026→Sep 28, 2026 (actual)
Oct 13, 2026
Eligibility
2 inclusion criteria edited
What changed in the criteria
Inclusion criteria
  • EditedAspartate aminotransferase (AST) ≤2.5 × ULULN.
  • EditedHas signed informed consent and isIs willing and able to sign informed consent and comply with the requirements and restrictions listed in the informed consent form and protocol.
Oct 13, 2026
Site contacts
Changed at 3 sites. See the sites
Show 3 sites
  • Michael G Oefelein Clinical Trials · Bakersfield, United StatesContact C•••@folioclinicalresearch.com · •••1063→s•••@folioclinicalresearch.com · •••1063
  • START Carolinas · Myrtle Beach, United StatesContact h•••@startresearch.com · •••1679→m•••@startresearch.com · •••1679
  • UPNT Research Institute · Arlington, United StatesContact K•••@objective.health · •••9624→g•••@folioclinicalresearch.com · •••9775
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Not yet recruiting→Recruiting
    5 sites added, 1 site removed. 10 sites changed recruiting status (5 now recruiting, 5 now not yet recruiting)
    Show 10 sites
    • East Valley Urology Center of Arizona · Queen Creek, United Statesno status→Recruiting
    • Michael G Oefelein Clinical Trials · Bakersfield, United Statesno status→Recruiting
    • Urology Center of Southern California · Murrieta, United Statesno status→Recruiting
    • Brigham and Women's Hospital · Boston, United Statesno status→Not yet recruiting
    • University of Nebraska Medical Center · Omaha, United Statesno status→Not yet recruiting
    • SUNY Upstate Medical University · Syracuse, United Statesno status→Not yet recruiting
    • University of Pennsylvania-Perelman Center for Advanced Medicine · Philadelphia, United Statesno status→Not yet recruiting
    • START Carolinas · Myrtle Beach, United Statesno status→Recruiting
    • UPNT Research Institute · Arlington, United Statesno status→Recruiting
    • Urology Austin · Austin, United Statesno status→Not yet recruiting
    Show 5 added (5 United States)
    • University of Colorado Cancer Center · Aurora, United States
    • University of Miami · Miami, United States
    • Michigan Institute of Urology · Troy, United States
    • Oregon Health & Science University · Portland, United States
    • Renovatio Clinical · The Woodlands, United States
    Show 1 removed
    • Ichan School of Medicine at Mount Sinai · New York, United States
    Start date Sep 30, 2026→Sep 28, 2026 (now actual)
    Eligibility 2 inclusion criteria edited
    What changed in the criteria
    Inclusion criteria
    • EditedAspartate aminotransferase (AST) ≤2.5 × ULULN.
    • EditedHas signed informed consent and isIs willing and able to sign informed consent and comply with the requirements and restrictions listed in the informed consent form and protocol.
    Site contacts Changed at 3 sites. See the sites
    Show 3 sites
    • Michael G Oefelein Clinical Trials · Bakersfield, United StatesContact C•••@folioclinicalresearch.com · •••1063→s•••@folioclinicalresearch.com · •••1063
    • START Carolinas · Myrtle Beach, United StatesContact h•••@startresearch.com · •••1679→m•••@startresearch.com · •••1679
    • UPNT Research Institute · Arlington, United StatesContact K•••@objective.health · •••9624→g•••@folioclinicalresearch.com · •••9775
    + 2 other changes: verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07725796
Lead sponsor
UroGen Pharma, Inc., a subsidiary of UroGen Pharma Ltd.
Responsible party
Sponsor
First posted
Jul 24, 2026
Start date
Sep 28, 2026
Primary completion
Aug 2, 2029 (estimated)
Completion
Aug 2, 2029 (estimated)
Last update
Oct 13, 2026

Study contacts

Heather Lansford
Contact
heather.lansford@urogen.com
610-226-5111
Sebastian Mirkin, MD
study director · UroGen Pharma

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion